{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:37:05Z","timestamp":1787773025088,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012739","name":"Zogenix","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012739","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ovid Therapeutics"},{"DOI":"10.13039\/100016814","name":"Marinus Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016814","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011112","name":"UCB US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010091","name":"International Foundation for CDKL5 Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010091","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Neurogene"},{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014942","name":"Novartis Gene Therapies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014942","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024580","name":"Orion Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024580","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031370","name":"Taysha Gene Therapies","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031370","id-type":"DOI","asserted-by":"crossref"}]},{"name":"FOXG1 Research Foundation"},{"name":"Anavex Life Science"},{"name":"Newron Pharmaceuticals"},{"DOI":"10.13039\/100018232","name":"Orphan Disease Center, Perelman School of Medicine, University of Pennsylvania","doi-asserted-by":"publisher","award":["CDKL5-19-D-101-3"],"award-info":[{"award-number":["CDKL5-19-D-101-3"]}],"id":[{"id":"10.13039\/100018232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001801","name":"University of Western Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40263-024-01105-z","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T22:02:31Z","timestamp":1722031351000},"page":"719-732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Caregiver Perspective of Benefits and Side Effects of Anti-Seizure Medications in CDKL5 Deficiency Disorder from an International Database"],"prefix":"10.1007","volume":"38","author":[{"given":"Kingsley","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Junaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather E.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia M.","family":"Pestana-Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajsekar R.","family":"Rajaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Downs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-5834","authenticated-orcid":false,"given":"Helen","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"issue":"6","key":"1105_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1474-4422(22)00035-7","volume":"21","author":"H Leonard","year":"2022","unstructured":"Leonard H, Downs J, Benke TA, Swanson L, Olson H, Demarest S. CDKL5 deficiency disorder: clinical features, diagnosis, and management. Lancet Neurol. 2022;21(6):563\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(22)00035-7.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1105_CR2","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/brain\/awz195","volume":"142","author":"JD Symonds","year":"2019","unstructured":"Symonds JD, Zuberi SM, Stewart K, McLellan A, O\u2019Regan M, MacLeod S, et al. Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort. Brain. 2019;142(8):2303\u201318. https:\/\/doi.org\/10.1093\/brain\/awz195.","journal-title":"Brain"},{"key":"1105_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pediatrneurol.2019.02.015","volume":"97","author":"HE Olson","year":"2019","unstructured":"Olson HE, Demarest ST, Pestana-Knight EM, Swanson LC, Iqbal S, Lal D, et al. Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol. 2019;97:18\u201325. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2019.02.015.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"1105_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/cge.13862","volume":"99","author":"CI MacKay","year":"2021","unstructured":"MacKay CI, Wong K, Demarest ST, Benke TA, Downs J, Leonard H. Exploring genotype-phenotype relationships in the CDKL5 deficiency disorder using an international dataset. Clin Genet. 2021;99(1):157\u201365. https:\/\/doi.org\/10.1111\/cge.13862.","journal-title":"Clin Genet"},{"issue":"3","key":"1105_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/ejhg.2012.156","volume":"21","author":"S Fehr","year":"2013","unstructured":"Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S, et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet. 2013;21(3):266\u201373. https:\/\/doi.org\/10.1038\/ejhg.2012.156.","journal-title":"Eur J Hum Genet"},{"issue":"17","key":"1105_CR6","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.3390\/ijms20174075","volume":"20","author":"I Barbiero","year":"2019","unstructured":"Barbiero I, De Rosa R, Kilstrup-Nielsen C. Microtubules: a key to understand and correct neuronal defects in CDKL5 deficiency disorder? Int J Mol Sci. 2019;20(17):4075. https:\/\/doi.org\/10.3390\/ijms20174075.","journal-title":"Int J Mol Sci"},{"key":"1105_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105176","volume":"148","author":"B Terzic","year":"2021","unstructured":"Terzic B, Cui Y, Edmondson AC, Tang S, Sarmiento N, Zaitseva D, et al. X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder. Neurobiol Dis. 2021;148: 105176. https:\/\/doi.org\/10.1016\/j.nbd.2020.105176.","journal-title":"Neurobiol Dis"},{"issue":"21","key":"1105_CR8","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1212\/wnl.0000000000003352","volume":"87","author":"S Fehr","year":"2016","unstructured":"Fehr S, Wong K, Chin R, Williams S, de Klerk N, Forbes D, et al. Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. Neurology. 2016;87(21):2206\u201313. https:\/\/doi.org\/10.1212\/wnl.0000000000003352.","journal-title":"Neurology"},{"issue":"8","key":"1105_CR9","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1111\/epi.16285","volume":"60","author":"ST Demarest","year":"2019","unstructured":"Demarest ST, Olson HE, Moss A, Pestana-Knight E, Zhang X, Parikh S, et al. CDKL5 deficiency disorder: relationship between genotype, epilepsy, cortical visual impairment, and development. Epilepsia. 2019;60(8):1733\u201342. https:\/\/doi.org\/10.1111\/epi.16285.","journal-title":"Epilepsia"},{"issue":"11","key":"1105_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13023-016-0418-y","volume":"14","author":"M Mangatt","year":"2016","unstructured":"Mangatt M, Wong K, Anderson B, Epstein A, Hodgetts S, Leonard H, et al. Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome. Orphanet J Rare Dis. 2016;14(11):39. https:\/\/doi.org\/10.1186\/s13023-016-0418-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"1105_CR11","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1002\/ajmg.a.37851","volume":"170","author":"S Fehr","year":"2016","unstructured":"Fehr S, Downs J, Ho G, de Klerk N, Forbes D, Christodoulou J, et al. Functional abilities in children and adults with the CDKL5 disorder. Am J Med Genet A. 2016;170(11):2860\u20139. https:\/\/doi.org\/10.1002\/ajmg.a.37851.","journal-title":"Am J Med Genet A"},{"key":"1105_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106521","volume":"169","author":"H Leonard","year":"2021","unstructured":"Leonard H, Junaid M, Wong K, Demarest S, Downs J. Exploring quality of life in individuals with a severe developmental and epileptic encephalopathy, CDKL5 deficiency disorder. Epilepsy Res. 2021;169: 106521. https:\/\/doi.org\/10.1016\/j.eplepsyres.2020.106521.","journal-title":"Epilepsy Res"},{"issue":"42","key":"1105_CR13","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.M606325200","volume":"281","author":"I Bertani","year":"2006","unstructured":"Bertani I, Rusconi L, Bolognese F, Forlani G, Conca B, De Monte L, et al. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J Biol Chem. 2006;281(42):32048\u201356. https:\/\/doi.org\/10.1074\/jbc.M606325200.","journal-title":"J Biol Chem"},{"issue":"1","key":"1105_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s11689-021-09384-z","volume":"13","author":"HE Olson","year":"2021","unstructured":"Olson HE, Daniels CI, Haviland I, Swanson LC, Greene CA, Denny AMM, et al. Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder. J Neurodev Disord. 2021;13(1):40. https:\/\/doi.org\/10.1186\/s11689-021-09384-z.","journal-title":"J Neurodev Disord"},{"issue":"6","key":"1105_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s40263-022-00921-5","volume":"36","author":"W Hong","year":"2022","unstructured":"Hong W, Haviland I, Pestana-Knight E, Weisenberg JL, Demarest S, Marsh ED, et al. CDKL5 deficiency disorder-related epilepsy: a review of current and emerging treatment. CNS Drugs. 2022;36(6):591\u2013604. https:\/\/doi.org\/10.1007\/s40263-022-00921-5.","journal-title":"CNS Drugs"},{"key":"1105_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.874695","volume":"13","author":"S Amin","year":"2022","unstructured":"Amin S, Monaghan M, Aledo-Serrano A, Bahi-Buisson N, Chin RF, Clarke AJ, et al. International consensus recommendations for the assessment and management of individuals with CDKL5 deficiency disorder. Front Neurol. 2022;13: 874695. https:\/\/doi.org\/10.3389\/fneur.2022.874695.","journal-title":"Front Neurol"},{"issue":"1","key":"1105_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ejpn.2015.09.001","volume":"20","author":"A Muller","year":"2016","unstructured":"Muller A, Helbig I, Jansen C, Bast T, Guerrini R, Jahn J, et al. Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. Eur J Paediatr Neurol. 2016;20(1):147\u201351. https:\/\/doi.org\/10.1016\/j.ejpn.2015.09.001.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"1105_CR18","first-page":"130","volume":"21","author":"S Amin","year":"2017","unstructured":"Amin S, Majumdar A, Mallick AA, Patel J, Scatchard R, Partridge CA, et al. Caregiver\u2019s perception of epilepsy treatment, quality of life and comorbidities in an international cohort of CDKL5 patients. Hippokratia. 2017;21(3):130\u20135.","journal-title":"Hippokratia"},{"issue":"4","key":"1105_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.braindev.2020.12.006","volume":"43","author":"Y Kobayashi","year":"2021","unstructured":"Kobayashi Y, Tohyama J, Takahashi Y, Goto T, Haginoya K, Inoue T, et al. Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants. Brain Dev. 2021;43(4):505\u201314. https:\/\/doi.org\/10.1016\/j.braindev.2020.12.006.","journal-title":"Brain Dev"},{"issue":"2","key":"1105_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41431-022-01163-1","volume":"31","author":"K Wong","year":"2023","unstructured":"Wong K, Junaid M, Demarest S, Saldaris J, Benke TA, Marsh ED, et al. Factors influencing the attainment of major motor milestones in CDKL5 deficiency disorder. Eur J Hum Genet. 2023;31(2):169\u201378. https:\/\/doi.org\/10.1038\/s41431-022-01163-1.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"1105_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/epi.12478","volume":"55","author":"SV Jain","year":"2013","unstructured":"Jain SV, Glauser TA. Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia. 2013;55(1):26\u201337. https:\/\/doi.org\/10.1111\/epi.12478.","journal-title":"Epilepsia"},{"key":"1105_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101559","volume":"60","author":"C Liguori","year":"2021","unstructured":"Liguori C, Toledo M, Kothare S. Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: a literature review. Sleep Med Rev. 2021;60: 101559. https:\/\/doi.org\/10.1016\/j.smrv.2021.101559.","journal-title":"Sleep Med Rev"},{"issue":"10","key":"1105_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","volume":"36","author":"A Strzelczyk","year":"2022","unstructured":"Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs. 2022;36(10):1079\u2013111. https:\/\/doi.org\/10.1007\/s40263-022-00955-9.","journal-title":"CNS Drugs"},{"issue":"5","key":"1105_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13600","volume":"31","author":"J Downs","year":"2022","unstructured":"Downs J, Jacoby P, Saldaris J, Leonard H, Benke T, Marsh E, et al. Negative impact of insomnia and daytime sleepiness on quality of life in individuals with the cyclin-dependent kinase-like 5 deficiency disorder. J Sleep Res. 2022;31(5): e13600. https:\/\/doi.org\/10.1111\/jsr.13600.","journal-title":"J Sleep Res"},{"issue":"5","key":"1105_CR25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","volume":"21","author":"EM Pestana-Knight","year":"2022","unstructured":"Pestana-Knight EM, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, et al. Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2022;21(5):417\u201327. https:\/\/doi.org\/10.1016\/S1474-4422(22)00077-1.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1105_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/epi.17826","volume":"65","author":"HE Olson","year":"2024","unstructured":"Olson HE, Amin S, Bahi-Buisson N, Devinsky O, Marsh ED, Pestana-Knight E, et al. Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: two-year open-label extension follow-up. Epilepsia. 2024;65(1):37\u201345. https:\/\/doi.org\/10.1111\/epi.17826.","journal-title":"Epilepsia"},{"issue":"2","key":"1105_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.pediatrneurol.2011.11.007","volume":"46","author":"BD Moseley","year":"2012","unstructured":"Moseley BD, Dhamija R, Wirrell EC, Nickels KC. Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations. Pediatr Neurol. 2012;46(2):101\u20135. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2011.11.007.","journal-title":"Pediatr Neurol"},{"key":"1105_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.yebeh.2019.02.013","volume":"94","author":"G Melikishvili","year":"2019","unstructured":"Melikishvili G, Epitashvili N, Tabatadze N, Chikvinidze G, Dulac O, Bienvenu T, et al. New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy. Epilepsy Behav. 2019;94:308\u201311. https:\/\/doi.org\/10.1016\/j.yebeh.2019.02.013.","journal-title":"Epilepsy Behav"},{"key":"1105_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107946","volume":"118","author":"A Aledo-Serrano","year":"2021","unstructured":"Aledo-Serrano A, Gomez-Iglesias P, Toledano R, Garcia-Penas JJ, Garcia-Morales I, Anciones C, et al. Sodium channel blockers for the treatment of epilepsy in CDKL5 deficiency disorder: findings from a multicenter cohort. Epilepsy Behav. 2021;118: 107946. https:\/\/doi.org\/10.1016\/j.yebeh.2021.107946.","journal-title":"Epilepsy Behav"},{"issue":"7","key":"1105_CR30","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1111\/epi.17630","volume":"64","author":"HE Olson","year":"2023","unstructured":"Olson HE, Demarest S, Pestana-Knight E, Moosa AN, Zhang X, Perez-Perez JR, et al. Epileptic spasms in CDKL5 deficiency disorder: delayed treatment and poor response to first-line therapies. Epilepsia. 2023;64(7):1821\u201332. https:\/\/doi.org\/10.1111\/epi.17630.","journal-title":"Epilepsia"},{"issue":"5","key":"1105_CR31","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/epi.17918","volume":"65","author":"R Korinthenberg","year":"2024","unstructured":"Korinthenberg R, Bast T, Haberlandt E, Stephani U, Strzelczyk A, Rucker G. Efficacy and safety of corticosteroids and ACTH in epileptic syndromes beyond infantile epileptic spasms syndrome (IESS): a systematic review and meta-analysis. Epilepsia. 2024;65(5):1155\u201375. https:\/\/doi.org\/10.1111\/epi.17918.","journal-title":"Epilepsia"},{"key":"1105_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108152","volume":"122","author":"T Dale","year":"2021","unstructured":"Dale T, Downs J, Wong K, Leonard H. The perceived effects of cannabis products in the management of seizures in CDKL5 deficiency disorder. Epilepsy Behav. 2021;122: 108152. https:\/\/doi.org\/10.1016\/j.yebeh.2021.108152.","journal-title":"Epilepsy Behav"},{"key":"1105_CR33","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eplepsyres.2018.07.013","volume":"146","author":"Z Lim","year":"2018","unstructured":"Lim Z, Wong K, Downs J, Bebbington K, Demarest S, Leonard H. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 deficiency disorder. Epilepsy Res. 2018;146:36\u201340. https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.07.013.","journal-title":"Epilepsy Res"},{"issue":"8","key":"1105_CR34","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/epi.13813","volume":"58","author":"Z Lim","year":"2017","unstructured":"Lim Z, Wong K, Olson HE, Bergin AM, Downs J, Leonard H. Use of the ketogenic diet to manage refractory epilepsy in CDKL5 disorder: experience of >100 patients. Epilepsia. 2017;58(8):1415\u201322. https:\/\/doi.org\/10.1111\/epi.13813.","journal-title":"Epilepsia"},{"key":"1105_CR35","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","volume":"86","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Verducci C, Thiele EA, Laux LC, Patel AD, Filloux F, et al. Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131\u20137. https:\/\/doi.org\/10.1016\/j.yebeh.2018.05.013.","journal-title":"Epilepsy Behav"},{"issue":"158","key":"1105_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/01621459.1927.10502953","volume":"22","author":"EB Wilson","year":"1927","unstructured":"Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc. 1927;22(158):209\u201312. https:\/\/doi.org\/10.1080\/01621459.1927.10502953.","journal-title":"J Am Stat Assoc"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01105-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01105-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01105-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T03:17:33Z","timestamp":1723346253000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01105-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01105-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"19 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. The International CDKL5 Disorder Database was funded by the International Foundation for CDKL5 Research, along with the Orphan Disease Centre at the University of Pennsylvania (CDKL5-19-D-101-3) for analytical support for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Heather E. Olson received consulting fees from Takeda Pharmaceuticals and Zogenix regarding the clinical trial design, Ovid Therapeutics regarding clinical trial results and Marinus Pharmaceuticals regarding CDKL5 deficiency disorder, and has done consulting for the FOXG1 Research Foundation. She is the site Principal Investigator for a trial with UCB Pharmaceuticals. Elia M. Pestana-Knight was a speaker and scientific advisory board member for Marinus Pharmaceuticals, for which she has received compensation. Rajsekar R. Rajaraman was a speaker\/consultant for Marinus Pharmaceuticals. He was also a consultant for UCB Pharmaceuticals and received funding from the International Foundation for CDKL5 Research. Jenny Downs provided consultancy for Marinus Pharmaceuticals, Neurogene, Ultragenyx Pharmaceutical, Acadia Pharmaceuticals, Novartis Gene Therapies, Orion Corporation and Taysha Gene Therapies; and for clinical trials with Anavex Life Science and Newron Pharmaceuticals. All consultancies are unrelated to this work, and all remuneration has been made to her department. Helen Leonard provided consultancy for Marinus Pharmaceuticals, Acadia Pharmaceuticals, Novartis Gene Therapies and Orion Corporation; and for clinical trials with Anavex Life Science and Newron Pharmaceuticals. All consultancies are unrelated to this work, and all remuneration has been made to her department. Kingsley Wong, Mohammed Junaid and Solomon Alexander have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Human Research Ethics Committee of the University of Western Australia provided approval for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the caregivers of individuals who participated in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors contributed to the study\u2019s conception and design. M.J., K.W. and S.A. performed material preparation, data collection and analysis. H.L., M.J. and K.W. wrote the first draft of the manuscript, and all authors commented on previous versions. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The dataset analysed during the current study are not publicly available but may be available from the corresponding author on reasonable request following an application to and with approval from the local ethics committee.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}